These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
384 related articles for article (PubMed ID: 25943066)
1. Next generation prophylactic human papillomavirus vaccines. Schiller JT; Müller M Lancet Oncol; 2015 May; 16(5):e217-25. PubMed ID: 25943066 [TBL] [Abstract][Full Text] [Related]
2. Developments in L2-based human papillomavirus (HPV) vaccines. Schellenbacher C; Roden RBS; Kirnbauer R Virus Res; 2017 Mar; 231():166-175. PubMed ID: 27889616 [TBL] [Abstract][Full Text] [Related]
3. Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles. Boxus M; Fochesato M; Miseur A; Mertens E; Dendouga N; Brendle S; Balogh KK; Christensen ND; Giannini SL J Virol; 2016 Jul; 90(14):6314-25. PubMed ID: 27147749 [TBL] [Abstract][Full Text] [Related]
4. In silico/In vivo analysis of high-risk papillomavirus L1 and L2 conserved sequences for development of cross-subtype prophylactic vaccine. Namvar A; Bolhassani A; Javadi G; Noormohammadi Z Sci Rep; 2019 Oct; 9(1):15225. PubMed ID: 31645650 [TBL] [Abstract][Full Text] [Related]
6. Characterization of an Escherichia coli-derived human papillomavirus type 16 and 18 bivalent vaccine. Gu Y; Wei M; Wang D; Li Z; Xie M; Pan H; Wu T; Zhang J; Li S; Xia N Vaccine; 2017 Aug; 35(35 Pt B):4637-4645. PubMed ID: 28736197 [TBL] [Abstract][Full Text] [Related]
7. Salmonella enterica serovar Typhi Ty21a expressing human papillomavirus type 16 L1 as a potential live vaccine against cervical cancer and typhoid fever. Fraillery D; Baud D; Pang SY; Schiller J; Bobst M; Zosso N; Ponci F; Nardelli-Haefliger D Clin Vaccine Immunol; 2007 Oct; 14(10):1285-95. PubMed ID: 17687110 [TBL] [Abstract][Full Text] [Related]
8. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials. Van Damme P; Leroux-Roels G; Simon P; Foidart JM; Donders G; Hoppenbrouwers K; Levin M; Tibaldi F; Poncelet S; Moris P; Dessy F; Giannini SL; Descamps D; Dubin G Vaccine; 2014 Jun; 32(29):3694-705. PubMed ID: 24674663 [TBL] [Abstract][Full Text] [Related]
9. Immunogenicity of a prophylactic quadrivalent human papillomavirus L1 virus-like particle vaccine in male and female adolescent transplant recipients. Gomez-Lobo V; Whyte T; Kaufman S; Torres C; Moudgil A Pediatr Transplant; 2014 May; 18(3):310-5. PubMed ID: 24484551 [TBL] [Abstract][Full Text] [Related]
10. New prophylactics human papilloma virus (HPV) vaccines against cervical cancer. Barra F; Leone Roberti Maggiore U; Bogani G; Ditto A; Signorelli M; Martinelli F; Chiappa V; Lorusso D; Raspagliesi F; Ferrero S J Obstet Gynaecol; 2019 Jan; 39(1):1-10. PubMed ID: 30370796 [TBL] [Abstract][Full Text] [Related]
11. Quadrivalent Human Papillomavirus Vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Markowitz LE; Dunne EF; Saraiya M; Lawson HW; Chesson H; Unger ER; ; MMWR Recomm Rep; 2007 Mar; 56(RR-2):1-24. PubMed ID: 17380109 [TBL] [Abstract][Full Text] [Related]
12. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening. Arbyn M; Dillner J J Clin Virol; 2007 Mar; 38(3):189-97. PubMed ID: 17258503 [TBL] [Abstract][Full Text] [Related]
13. Papillomavirus-like particle based vaccines: cervical cancer and beyond. Schiller JT; Lowy DR Expert Opin Biol Ther; 2001 Jul; 1(4):571-81. PubMed ID: 11727495 [TBL] [Abstract][Full Text] [Related]
14. Minor Capsid Protein L2 Polytope Induces Broad Protection against Oncogenic and Mucosal Human Papillomaviruses. Pouyanfard S; Spagnoli G; Bulli L; Balz K; Yang F; Odenwald C; Seitz H; Mariz FC; Bolchi A; Ottonello S; Müller M J Virol; 2018 Feb; 92(4):. PubMed ID: 29212932 [TBL] [Abstract][Full Text] [Related]
15. Present status of human papillomavirus vaccine development and implementation. Herrero R; González P; Markowitz LE Lancet Oncol; 2015 May; 16(5):e206-16. PubMed ID: 25943065 [TBL] [Abstract][Full Text] [Related]
16. Virus-like Particle-Based L2 Vaccines against HPVs: Where Are We Today? Yadav R; Zhai L; Tumban E Viruses; 2019 Dec; 12(1):. PubMed ID: 31877975 [TBL] [Abstract][Full Text] [Related]
17. Preclinical refinements of a broadly protective VLP-based HPV vaccine targeting the minor capsid protein, L2. Tumban E; Muttil P; Escobar CA; Peabody J; Wafula D; Peabody DS; Chackerian B Vaccine; 2015 Jun; 33(29):3346-53. PubMed ID: 26003490 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis. Simms KT; Laprise JF; Smith MA; Lew JB; Caruana M; Brisson M; Canfell K Lancet Public Health; 2016 Dec; 1(2):e66-e75. PubMed ID: 29253419 [TBL] [Abstract][Full Text] [Related]
19. Bacterially expressed human papillomavirus type 6 and 11 bivalent vaccine: Characterization, antigenicity and immunogenicity. Pan H; Li Z; Wang J; Song S; Wang D; Wei M; Gu Y; Zhang J; Li S; Xia N Vaccine; 2017 May; 35(24):3222-3231. PubMed ID: 28483196 [TBL] [Abstract][Full Text] [Related]
20. Control of HPV infection and related cancer through vaccination. Tran NP; Hung CF; Roden R; Wu TC Recent Results Cancer Res; 2014; 193():149-71. PubMed ID: 24008298 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]